Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral solution NRT

This article was originally published in The Tan Sheet

Executive Summary

FDA denies Nico Worldwide's petition to file ANDAs for its nicotine oral solution, citing a need for human clinical trials to determine safety and efficacy. The Pacific Palisades, Calif.-based firm compared its generic nicotine polacrilex 2 mg and 4 mg base per 240 mL oral solutions to GlaxoSmithKline's Commit nicotine lozenges in the ANDA suitability petitions (1"The Tan Sheet" Aug. 2, 2004, In Brief). The oral solution is "unlikely to be bioequivalent to the approved lozenge" due to the different sites of absorption for the GSK and Nico Worldwide products, FDA states...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS098330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel